Suzhou, China, Aug 13, 2025 – CANbridge Pharmaceuticals Inc. (1228.HK), a global biopharmaceutical company, with a foundation in China, committed to the research, development and commercialization of transformative therapies to treat rare diseases, today announced that it has entered into a subscription agreement for the sale of approximately HK$100 million of shares at a price of HK$1.34 per Subscription Share to Qingdao Baheal Medical Inc. (Baheal Medical, “301015.SZ”), a leading the innovation brand commercialization platform in China. This strategic equity financing is aimed at optimizing CANbridge’s commercial business model and enhancing CANbridge’s commercial capabilities. In parallel, CANbridge and Baheal Medical have expanded strategic collaboration through an exclusive commercial services agreement, under which a Baheal Medical subsidiary will serve as the exclusive CSO for certain CANbridge products in mainland China, Hong Kong, and Macau (the “Relevant Regions”), with the option for Baheal affiliates to act as distributors in these markets.

Under the terms of the Subscription Agreement, CANbridge will issue 74,971,468 new Shares to the Subscriber at a subscription price of HK$1.34 per Share. Upon completion of the subscription, the Subscription Shares will represent approximately 17.65% of the company’s existing issued share capital and approximately 14.99% of the enlarged share capital.

James Xue, Ph.D., CANbridge Founder, Chairman, and CEO, said: “We are pleased to announce the strategic partnership with Baheal Medical.  As a leading brand commercialization platform in China, Baheal’s extensive network and capabilities will allow CANbridge to expand and scale our commercial activities for accelerating the market adoption of our commercial stage products.  The equity investment comes at a critical time for CANbridge. The proceeds from this financing will be allocated to advance the commercialization of our marketed products as well as to strengthen our working capital and improve operations outcomes.  Both the partnership and equity investment will help enhance our leading position in the China rare disease market.”  

Mr. Fu Gang, Chairman and General Manager of Baheal Medical, said: “CANbridge has demonstrated outstanding achievements in China's rare disease field. We are pleased to make this strategic investment and establish a business collaboration with CANbridge .We believe that the effective implementation of this collaboration will enhance the sustainable profitability of both parties and deliver a positive impact on business performance.”

About CANbridge Pharmaceuticals Inc.  

CANbridge Pharmaceuticals Inc. (HKEX:1228) is a global biopharmaceutical company, with a foundation in China, committed to the research, development and commercialization of transformative therapies for rare disease. CANbridge has a differentiated drug portfolio, with 3 approved drugs and a pipeline of 7 assets, targeting prevalent rare disease indications that have unmet needs and significant market potential. These include Hunter syndrome and other lysosomal storage disorders, complement-mediated disorders, hemophilia A, metabolic disorders, rare cholestatic liver diseases and neuromuscular diseases. The CANbridge Next-Generation Innovation and Process Development Facility is developing novel, potentially curative, gene therapies for rare genetic diseases, including Pompe disease, Fabry disease, Duchenne muscular dystrophy (DMD) and other neuromuscular conditions, and collaborates with world-leading researchers and biotech companies. CANbridge global partners include: Apogenix, GC Pharma, Mirum, Wuxi Biologics, Privus, UMass Chan Medical School, the University of Washington School of Medicine and Scriptr Global.

For more on CANbridge Pharmaceuticals Inc., please go to: www.canbridgepharma.com.

Forward - Looking Statements

The forward - looking statements made in this article are only related to the events or information as of the date of making the statements in this article. Unless required by law, we have no obligation to publicly update or revise any forward - looking statements, whether due to new information, future events, or other reasons, after the date of the data on which the statements are based or to reflect the occurrence of unforeseen events. You should read this article in its entirety and be aware that our actual future results or performance may differ materially from our expectations. In this article, any statements or references to the intentions of us, any of our directors, or our company are made as of the date of this article. Any of these intentions may change with future developments.

Contact:

China Investor Relations

CANbridge Pharmaceuticals Inc.

ir@canbridgepharma.com